Artwork

コンテンツは Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!

Episode 55. ASH 2024 Myeloma Updates with Dr. Rakesh Popat

38:26
 
シェア
 

Manage episode 460548061 series 3369804
コンテンツは Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed:

1. AQUILA Trial in High-Risk SMM

  • Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring.
  • Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara.
  • Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm.
  • Read the abstract.
  • Read the simultaneous publication at NEJM.

2. Anito-Cel: New BCMA CAR T Therapy

  • Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T.
  • Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns.
  • Read the abstract.

3. CARTITUDE-4 Update

  • Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care.
  • Read the abstract.

4. ANDROMEDA OS Data in AL Amyloidosis

  • Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis.
  • Insights into cardiac responses and crossover impact.
  • Read the abstract.

5. OPTIMUM Trial in Ultra-High-Risk NDMM

  • Five-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents.
  • Subgroup outcomes highlighting both challenges and exceptional results.
  • Read the abstract

6. GMMG-HD7 Trial PFS Update

7. Exciting New Drugs

  • Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody.
  • Expert insights into their efficacy and potential to reshape myeloma care.
  • Read the abstract

  continue reading

57 つのエピソード

Artwork
iconシェア
 
Manage episode 460548061 series 3369804
コンテンツは Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed:

1. AQUILA Trial in High-Risk SMM

  • Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring.
  • Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara.
  • Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm.
  • Read the abstract.
  • Read the simultaneous publication at NEJM.

2. Anito-Cel: New BCMA CAR T Therapy

  • Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T.
  • Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns.
  • Read the abstract.

3. CARTITUDE-4 Update

  • Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care.
  • Read the abstract.

4. ANDROMEDA OS Data in AL Amyloidosis

  • Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis.
  • Insights into cardiac responses and crossover impact.
  • Read the abstract.

5. OPTIMUM Trial in Ultra-High-Risk NDMM

  • Five-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents.
  • Subgroup outcomes highlighting both challenges and exceptional results.
  • Read the abstract

6. GMMG-HD7 Trial PFS Update

7. Exciting New Drugs

  • Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody.
  • Expert insights into their efficacy and potential to reshape myeloma care.
  • Read the abstract

  continue reading

57 つのエピソード

Alle episoder

×
 
Loading …

プレーヤーFMへようこそ!

Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。

 

クイックリファレンスガイド

探検しながらこの番組を聞いてください
再生